Abbott Laboratories (ABT) Could Be 10% Undervalued On Its $1.35b Buyback Update

Abbott Laboratories (ABT) has completed a $1.35 billion share buyback, repurchasing over 14 million shares. Despite recent short-term gains, the company's shares are considered 9.5% undervalued, with a fair value estimated at $119.13 compared to its current price of $107.81. Growth drivers include expanding healthcare access and rising middle classes in emerging markets, although risks like pricing pressure and foreign exchange fluctuations remain.